UBS Knock-Out BAYN/ DE000UH08S90 /
10/8/2024 7:32:17 PM | Chg.-0.050 | Bid9:30:21 PM | Ask9:30:21 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.510EUR | -8.93% | 0.520 Bid Size: 45,000 |
0.530 Ask Size: 45,000 |
BAYER AG NA O.N. | 24.2086 EUR | 12/31/2078 | Call |
GlobeNewswire
8/2
Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting A...
GlobeNewswire
7/11
AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational...
GlobeNewswire
5/30
Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
GlobeNewswire
5/30
BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’...
GlobeNewswire
5/2
AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting...
GlobeNewswire
4/18
AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in conge...
GlobeNewswire
4/16
AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’...
GlobeNewswire
4/11
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from...
GlobeNewswire
3/25
BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rar...
GlobeNewswire
3/6
BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive tren...
GlobeNewswire
3/4
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
GlobeNewswire
2/13
Corporate Alignment with Climate Goals Under Scrutiny: LyondellBasell & Bayer demonstrate good pract...